BioTrinity Ventures to the Capital

News provided by

OBN

16 May, 2013, 16:18 GMT

ABINGDON, England, May 16, 2013 /PRNewswire/ --

BioTrinity 2013 the Most Successful Yet: Move to London as Growth Continues  

OBN, the membership organisation supporting and bringing together the UK's emerging life sciences companies, corporate partners and investors, announces today that BioTrinity, its annual conference, is moving to London in 2014 to meet growing demand as it reports further year-on-year growth of delegates.

Jon Rees, CEO of OBN, said: "The impressive annual growth of BioTrinity means that we now need a larger venue as we continue to expand our offering and deliver the best possible programme for emerging life sciences companies. Newbury Racecourse has been an excellent venue, at which we grew BioTrinity by nearly 50%, and I look forward to the move to the Capital as we expand our footprint in the UK lifesciences sector and serve the increased interest we are seeing internationally."

BioTrinity 2013 attendance reflected its position as a key conference in European biopartnering:

  • 880 delegates from over 510 companies from 28 countries across Europe, Asia and North America;
  • Participation of nearly 100 delegates from 80 investment firms from 10 countries (up 20%) specialising in funding emerging biotechnology and life science companies as  well as more than 50 pharmaceutical company delegates;
  • 87 company pitches for partners and investment (up 16%), among 160 speakers (up 23%) throughout the two-day conference
  • This year saw more than 1700 one-to-one partnering meetings scheduled, continuing the growth trend from 500 meetings in 2008
  • 14 specialised workshops

About OBN

OBN is the membership organisation supporting and bringing together the UK's emerging life science companies, corporate partners and investors within the Golden Triangle biocluster (formed by the cities of Oxford, Cambridge and London) and beyond, providing networking, partnering, group purchasing, advocacy and cluster consultancy.

Through our delivery of Europe's 3rd largest annual biopartnering and investment conference 'BioTrinity', which attracts 900 delegates from 30 countries, OBN generates more R&D-company-to-investor interactions than anyone else in Europe.

For further information on OBN and its activities, please visit: http://www.obn.org.uk or to find out more about BioTrinity, please visit http://www.biotrinity.com